DelveInsight’s “Alopecia Areata Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Alopecia Areata pipeline landscapes. It comprises Alopecia Areata pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alopecia Areata therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alopecia Areata pipeline products.
Some of the key takeaways of the Alopecia Areata Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly and Company/Incyte Corporation, Alcaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, etc., are developing therapies for the treatment of Alopecia Areata.
-
Emerging therapies such as PF-06651600, Jaktinib, Baricitinib, ATI-502, LH-8, CTP-543,are expected to have a significant impact on the Alopecia Areata market in the coming years.
Get an overview of pipeline landscape @ Alopecia Areata Clinical Trials Analysis
Alopecia Areata Overview
Alopecia Areata (AA) is a common autoimmune skin disease, which causes hair loss on the scalp, face, and at times on other areas of the body. The affected hair follicles are attacked by a person’s immune system (white blood cells), which results in the seizing of the hair growth stage. Hair follicles remain alive, and hair can regrow at any time in Alopecia Areata. Alopecia Areata usually begins with one or more patches which may be small, round, smooth on the scalp that can progress to total scalp hair loss or complete body hair loss. Genetic predisposition and environmental factors increase the chances of developing Alopecia Areata.
Alopecia Areata Emerging Drugs
-
PF-06651600: Pfizer
-
Jaktinib: Suzhou Zelgen Biopharmaceuticals
-
Baricitinib: Eli Lilly and Company/Incyte Corporation
-
ATI-502: Alcaris Therapeutics
-
LH-8: Legacy Healthcare
-
CTP-543: Concert Pharmaceuticals
For further information, refer to the detailed report @ Alopecia Areata Pipeline Therapeutics
Scope of Alopecia Areata Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly and Company/Incyte Corporation, Alcaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, and others.
-
Pipeline Therapies: PF-06651600, Jaktinib, Baricitinib, ATI-502, LH-8, CTP-543, and others.
Table of Contents
|
1 |
Alopecia Areata Report Introduction |
|
2 |
Alopecia Areata Executive Summary |
|
3 |
Alopecia Areata Overview |
|
4 |
Alopecia Areata- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Alopecia Areata Pipeline Therapeutics |
|
6 |
Alopecia Areata Late Stage Products (Phase II/III) |
|
7 |
Alopecia Areata Mid Stage Products (Phase II) |
|
8 |
Alopecia Areata Early Stage Products (Phase I) |
|
9 |
Alopecia Areata Preclinical Stage Products |
|
10 |
Alopecia Areata Therapeutic Assessment |
|
11 |
Alopecia Areata Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Alopecia Areata Key Companies |
|
14 |
Alopecia Areata Key Products |
|
15 |
Alopecia Areata Unmet Needs |
|
16 |
Alopecia Areata Market Drivers and Barriers |
|
17 |
Alopecia Areata Future Perspectives and Conclusion |
|
18 |
Alopecia Areata Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Alopecia Areata Drugs Pipeline Report
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/